Trastuzumab deruxtecan (T-DXd) is the first HER2-targeted agent to show clinical efficacy in HER2-mutant non-small cell lung cancer (HER2m NSCLC). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.